This is a working overview of growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, as part of transgender hormone therapy, or to perform chemical castration of violent sex offenders. It is given by injection into a muscle or under the skin. Leuprorelin is in the gonadotropin-releasing hormone (GnRH) analogue family of medications. It works by decreasing gonadotropins, thereby decreasing testosterone and estradiol. Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. Use during pregnancy may harm foetal development. Leuprorelin was patented in 1973 and approved for medical use in the United States in 1985. It is on the World Health Organization's List of Essential Medicines. It is sold under the brand name Lupron, among others.
glycolipid Any of a subclass of lipids consisting of a central polar molecule (most commonly glycerol or sphingosine) which is covalently attached to one or more monosaccharides or oligosaccharides via glycosidic bonds, as well as to one or more long, non-polar fatty acid chains. Glycolipids are one of three major types of membrane lipid comprising all biological membranes, along with phospholipids and cholesterol.
== Manifestations of chirality == Flavor: the artificial sweetener aspartame has two enantiomers. L-aspartame tastes sweet whereas D-aspartame is tasteless. Odor: R-(–)-carvone smells like spearmint whereas S-(+)-carvone smells like caraway. Drug effectiveness: the antidepressant drug citalopram is sold as a racemic mixture. However, studies have shown that only the (S)-(+) enantiomer (escitalopram) is responsible for the drug's beneficial effects. Drug safety: D‑penicillamine is used in chelation therapy and for the treatment of rheumatoid arthritis whereas L‑penicillamine is toxic as it inhibits the action of pyridoxine, an essential B vitamin.
Sources: en.wikipedia.org
=== July === July 1 Trade Representative Jamieson Greer announces that the US will not renew the USMCA free trade agreement signed during Trump's first administration. Trump takes his first flight in the new Air Force One, which was gifted by Qatar. Three American soldiers are injured and one soldier is missing after their MH-60S Seahawk helicopter went down in the Arabian Sea. July 3 2026 North American heat wave: Heat waves are reported across the eastern and central United States, with Independence Day celebrations cancelled or postponed including the Great American State Fair on the National Mall. Around 23 U.S. states are placed under heat warnings by the National Weather Service. A man dies after setting himself on fire outside the UN in New York, with activists and reports identifying him as a pro-Tibet advocate. Democrat Harry Benton resigns from the Illinois House of Representatives after allegations of misconduct.
=== Arrest attempts and later events === On 15 March 2010, Messina Denaro's brother, Salvatore Messina Denaro, was arrested along with 18 others in operation "Golem 2". They were part of a network surrounding the Mafia boss and were charged with organizing Messina Denaro's secret correspondence in order to help him remain hidden. Other charges include mafia association, corruption and protection rackets. On 19 May 2011, an attempt to arrest Messina Denaro failed. Police surrounded a manor farm ten minutes from his hometown, Castelvetrano. They were tipped by the secret service Agenzia Informazioni e Sicurezza Interna which had provided useful information for the previous arrests of Mafia bosses Giuseppe Falsone and Gerlandino Messina. However, there was no trace of Messina Denaro. In 2012, though still at large, Messina Denaro was one of five people sentenced to life imprisonment for their roles in the murder of Giuseppe Di Matteo. On 13 December 2013, Messina Denaro's sister, Patrizia Messina Denaro, was arrested along with several other mafia associates in a serious blow to Messina Denaro by Italian police. On 17 April 2018, she was sentenced to 14 years in prison for mafia association, external competition, and attempted extortion. In December 2014, there was a mention of Italian police coming close to apprehending Messina Denaro after they made an estimated €20 million seizure of his assets in the form of valuable olive groves in Trapani. Wiretaps had revealed Messina Denaro was receiving funding from the Fountain of Gold olive oil business based in the region.
=== Radio === Following stints working in radio in Southern California and Honolulu, French became morning DJ on the Seattle radio station KIRO in 1959. He left KIRO in 1971 and moved to KVI, where he produced and wrote radio dramas. French was dismissed from his position at KVI in 1978, and he returned to KIRO in as a host 1980. He stepped down from his position as a host in 1994. In 1996, French began production of the radio drama program Imagination Theatre, which in 2003 moved to KIXI. His syndicated programs are now broadcast on over 120 stations in the U.S. and Canada and are also broadcast via XM Satellite Radio throughout North America. In January 2017, it was announced that, due to age and health issues, French and his family would be closing down their production company, Jim French Productions, and discontinuing all broadcasts of Imagination Theatre at the end of March 2017. Imagination Theatre was relaunched in 2019, following a successful crowdfunding campaign headed by actors and producers John Patrick Lowrie and Larry Albert, and is now produced by Aural Vision, LLC.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.